Taken together, it is evident that the TMPRSS2–ERG fusion holds a central role in the onset and progression of prostate cancer, with ERG serving as a pivotal hub for DDR/Hippo/Notch pathways, all actively implicated in prostate cancer pathophysiology. This evidence concerns the gene ERG and prostate cancer.